Chronic myeloid leukemia with p190BCR-ABL: Prevalence, morphology, tyrosine kinase inhibitor response, and kinase domain mutation analysis

Blood

Volumn 114, Issue 16, 2009, Pages 3502-3503

  Pardanani, Animesh ^a   Tefferi, Ayalew ^a   Litzow, Mark R ^a   Zent, Clive ^a   Hogan, William J ^a   McClure, Rebecca F ^a   Viswanatha, David ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BCR ABL PROTEIN; BCR ABL TYROSINE KINASE; BCR-ABL TYROSINE KINASE; PROTEIN KINASE INHIBITOR; PROTEIN TYROSINE KINASE;

AGED; BIOSYNTHESIS; CHRONIC MYELOID LEUKEMIA; COHORT ANALYSIS; DRUG EFFECT; GENE EXPRESSION REGULATION; GENETICS; HUMAN; LETTER; MALE; METABOLISM; MIDDLE AGED; MUTATION; NUCLEOTIDE SEQUENCE; PROTEIN TERTIARY STRUCTURE;

AGED; COHORT STUDIES; DNA MUTATIONAL ANALYSIS; FUSION PROTEINS, BCR-ABL; GENE EXPRESSION REGULATION, LEUKEMIC; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MALE; MIDDLE AGED; MUTATION; PROTEIN KINASE INHIBITORS; PROTEIN STRUCTURE, TERTIARY; PROTEIN-TYROSINE KINASES;

EID: 70350717759     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2009-07-234666     Document Type: Letter

References (5)

1. Ravandi F, Cortes J, Albitar M, et al. Chronic myelogenous leukaemia with p185(BCR/ABL) expression: characteristics and clinical significance. Br J Haematol. 1999;107:581-586.
2. Melo JV. The diversity of BCR-ABL fusion proteins and their relationship to leukemia phenotype. Blood. 1996;88:2375-2384.
3. Melo JV, Myint H, Galton DA, Goldman JM. P190BCR-ABL chronic myeloid leukaemia: the missing link with chronic myelomonocytic leukaemia? Leukemia. 1994;8:208-211.
4. Roumier C, Daudignon A, Soenen V, et al. p190 bcr-abl rearrangement: a secondary cytogenetic event in some chronic myeloid disorders? Haematologica. 1999;84:1075-1080.
5. Verma D, Kantarjian HM, Jones D, et al. Chronic myeloid leukemia (CML) with P190BCR-ABL - analysis of characteristics, outcomes and prognostic significance. Blood. 2009;114:2232-2235.